



Cite this: *RSC Chem. Biol.*, 2025, 6, 295

## The molecular features of non-peptidic nucleophilic substrates and acceptor proteins determine the efficiency of sortagging†

Tetiana Bondarchuk, <sup>ab</sup> Elena Zhuravel, <sup>a</sup> Oleh Shyshlyk, <sup>ac</sup> Mykhaylo O. Debelyy, <sup>a</sup> Oleksandr Pokholenko, <sup>ad</sup> Diana Vaskiv, <sup>a</sup> Alla Pogribna, <sup>ae</sup> Mariana Kuznietsova, <sup>a</sup> Yevhenii Hrynyshyn, <sup>a</sup> Oleksandr Nedialko, <sup>af</sup> Volodymyr Brovarets<sup>c</sup> and Sergey A. Zozulya <sup>\*a</sup>

Sortase A-mediated ligation (SML) or “sortagging” has become a popular technology to selectively introduce structurally diverse protein modifications. Despite the great progress in the optimization of the reaction conditions and design of miscellaneous C- or N-terminal protein modification strategies, the reported yields of conjugates are highly variable. In this study, we have systematically investigated C-terminal protein sortagging efficiency using a combination of several rationally selected and modified acceptor proteins and a panel of incoming surrogate non-peptidic amine nucleophile substrates varying in the structural features of their amino linker parts and cargo molecules. Our data suggest that the sortagging efficiency is modulated by the combination of molecular features of the incoming nucleophilic substrate, including the ionization properties of the reactive amino group, structural recognition of the nucleophilic amino linker by the enzyme, as well as the molecular nature of the attached payload moiety. Previous reports have confirmed that the steric accessibility of the C-terminal SrtA recognition site in the acceptor protein is also the critical determinant of sortase reaction efficiency. We suggest a computational procedure for simplifying *a priori* predictions of sortagging outcomes through the structural assessment of the acceptor protein and introduction of a peptide linker, if deemed necessary.

Received 9th October 2024,  
Accepted 19th December 2024

DOI: 10.1039/d4cb00246f

rsc.li/rsc-chembio

### Introduction

Targeted modification of proteins has always played a pivotal role in both the academic efforts to elucidate their biological function and many practical applications. For this purpose, in addition to engineering proteins by traditional molecular

biological means, a large variety of biophysical and biochemical probes represented by small molecules of non-peptidic origin, such as biotin, fluorescent dyes, isotope labels, drugs, sugars, lipids, and click-chemistry reagents, were introduced into a multitude of protein entities by miscellaneous bioconjugation methods. Quickly evolving enzymatic techniques more and more frequently displace the conventional chemical bioconjugation methods due to their advantageous lack of stochasticity and imprecision, as well as milder reaction conditions. One of the most popular enzymatic tools for N- or C-terminal protein modifications is Sortase A (SrtA) from *Staphylococcus aureus*, a representative of the family of transpeptidases from Gram-positive bacteria catalyzing the covalent anchoring of certain surface proteins to the bacterial cell envelope peptidoglycan. The main structural requirements for this sortase-mediated ligation are the presence of five amino acid long SrtA recognition motif LPXTG, where X is any amino acid, at the C-terminus of the N-terminal “acceptor” protein, and at least one N-terminal glycine residue at the C-terminal incoming nucleophilic component of the reaction. During the catalytic transpeptidation, the amide bond between the threonine and glycine

<sup>a</sup> Enamine Ltd, 78 Winston Churchill Street, Kyiv 02094, Ukraine.

E-mail: [s.zozulya@enamine.net](mailto:s.zozulya@enamine.net); Tel: +380 67 656-4026;

Web: <https://www.enamine.net>

<sup>b</sup> Department of Structural and Functional Proteomics, Institute of Molecular Biology and Genetics, 150 Zabolotnogo Street, Kyiv 03680, Ukraine

<sup>c</sup> V. P. Kukhar Institute of Bioorganic Chemistry and Petrochemistry,

1 Academician Kukhar Street, Kyiv 02094, Ukraine

<sup>d</sup> Taras Shevchenko National University of Kyiv, Department of Chemistry, 64 Volodymyrska Street, Kyiv, 01033, Ukraine

<sup>e</sup> Department of Cell Signal Systems, Institute of Molecular Biology and Genetics, 150 Zabolotnogo Street, Kyiv 03680, Ukraine

<sup>f</sup> V. N. Karazin Kharkiv National University, 4 Svobody Square, Kharkiv 61022, Ukraine

† Electronic supplementary information (ESI) available: Supplementary figures and tables, and supplementary methods. See DOI: <https://doi.org/10.1039/d4cb00246f>

residues in the recognition (“sortagging”) site is cleaved and a labile thioester product is formed with participation of the threonine carboxyl group and cysteine 184 in the enzyme active site. The thioester intermediate is resolved *via* a nucleophilic attack by the amino group of the N-terminal Gly in the incoming substrate resulting in the formation of a new amide bond in a covalent fusion.<sup>1,2</sup> Since the discovery of this enzyme in 1999<sup>3</sup> and its first experimental use for *in vitro* protein ligations,<sup>4</sup> a multitude of methods for N- and C-terminal or internal protein and peptide ligations, including non-natural C–C and N–N linkages, cyclization, multimerization, as well as targeted attachment of proteins to a wide variety of non-peptidic cargo molecules, supramolecular structures or surfaces, were developed, as discussed in detail in several recent reviews.<sup>1,5–10</sup> Limitations of the native enzyme such as its calcium-dependence, modest catalytic rates and lack of robustness, as well as stringent recognition of the canonical sortagging motif, were successfully eliminated by protein engineering/directed evolution. This led to the advent of multiply mutated, functionally superior versions of SrtA from *S. aureus*, supplemented by the gradual introduction of divergent sortases from other genera of Gram-positive bacteria, into sortagging practice.<sup>6</sup> A number of inventive ways to suppress formation of the hydrolytic side-products of SML to increase the target conjugate yields and to simplify purification were reported.<sup>6,8</sup> Another exciting area of innovation is the expanding use of (oligo)glycine surrogates of non-peptide origin as nucleophilic SML substrates,<sup>11–15</sup> which opens up access to a

much greater diversity of targeted chemical modifications for proteins.

Despite the substantial progress in methodology, the relationships between the molecular properties of acceptor proteins and incoming nucleophiles and the efficiency of sortagging, particularly in the case of non-canonical, synthetic surrogate substrates decorated with amino groups, are poorly understood. The main goal of this study was to shed more light on this understudied practically important aspect of SML technology.

## Results

The studied panel of sortagging acceptors consisted of proteins substantially different in their sizes, tertiary structures and functions (Table 1 and Fig. 1). Human epidermal growth factor (EGF) is a small monomeric polypeptide hormone functioning through binding its cognate cell surface receptor and inducing its dimerization. EGF is just 53 amino acids long (MW 6045 Da), and it has three intramolecular disulfide bonds. The soluble form of human tumour necrosis factor alpha (TNF $\alpha$ ) is a much larger pro-inflammatory cytokine forming stable homotrimers (MW 51 kDa) in solution. Human carbonic anhydrase, type II (CAHII) is a monomeric and relatively small (MW 29.2 kDa) intracellular enzyme. In our initial attempts to utilize Sortase A for labelling these three recombinantly produced proteins,

**Table 1** Amino acid sequences of the recombinant proteins used in this work. Non-natural parts of the proteins, including SrtA recognition sites, 6xHIS tags and spacers are shown in bold. Peptide linker sequences are underlined

**EGF-Srt** (59 aa)

NSDSECPLSHDGYCLHDGVCMYIEALDKYACNCVVGYIGERCQYRDLKWELR**LPETGG**

**CAHII-Srt-6H** (271 aa)

SHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIRDTHTAKYDPSLKPLSVSYDQATSLRILNNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLD  
GQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDLGLAVLGIFFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPP  
LLECCTWIVLKEPISVSSEQLKFRKLNFnGEPEELMVNDWRPAQPLKRNQIKASF**LPETGGHHHHHH**

**CAHII-GS-Srt-6H** (281 aa)

SHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIRDTHTAKYDPSLKPLSVSYDQATSLRILNNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLD  
GQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDLGLAVLGIFFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPP  
LLECCTWIVLKEPISVSSEQLKFRKLNFnGEPEELMVNDWRPAQPLKRNQIKASF**GGGGSGGGGS**LPETGGHHHHHH

**CAHII-PAS-Srt-6H** (321 aa)

SHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIRDTHTAKYDPSLKPLSVSYDQATSLRILNNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLD  
GQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDLGLAVLGIFFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPP  
LLECCTWIVLKEPISVSSEQLKFRKLNFnGEPEELMVNDWRPAQPLKRNQIKASF**AASSSSAPPAPASSPSAAPSAPASSASSASAAPASSAS**  
**AAASSPAPSL**PETGGHHHHHH

**TNF $\alpha$ -Srt** (162 aa)

VRSSSRTPSDKPVAHVANPQAEGQLQWLNRANALLANGVELRDNQLVVPSEGLYLIYSQVLFKGQGCPSTHVLLLTHTISRIA VSYQTKVNLLSAIKSP  
CQRETPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGII**LPETGG**


**TNF $\alpha$ -GS-Srt** (172 aa)

VRSSSRTPSDKPVAHVANPQAEGQLQWLNRANALLANGVELRDNQLVVPSEGLYLIYSQVLFKGQGCPSTHVLLLTHTISRIA VSYQTKVNLLSAIKSP  
CQRETPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGII**GGGGSGGGGS**LPETGG

**VHH\_7D12-Srt-6H** (142 aa)

**KI**GSQVKLEESGGGSVQTGGSLRLTCAASGRTSRSYGMGWFQRQAPGKEREFVSGISWRGDSTGYADSVKGRFTISRDNAKNTVDLQMNLSKPEDTAIYYC  
AAAAGSAWYGTLYEYDYWGQGTQTVSS**ASLPETGGHHHHHH**





**Fig. 1** PyMOL visualizations of the three-dimensional structures of EGF, TNF $\alpha$ , CAHII and VHH 7D12 modelled with the recombinant C-terminal appendages. (A) Side view of the I-TASSER model of the anti-epidermal growth factor receptor nanobody (VHH\_7D12-SRT-6H). (B) Side view of the I-TASSER model of human epidermal growth factor (EGF-SRT). (C) Side and front views of the I-TASSER model of human tumor necrosis factor- $\alpha$  (TNF $\alpha$ -SRT). (D) Side and front views of the I-TASSER model of human carbonic anhydrase II (CAHII-SRT-6H). Positions of the SrtA recognition sites are highlighted in red, and 6xHis tags are shown in yellow. In all cases, the initial recombinant structures with the shortest C-terminal additions (VHH\_7D12-SRT-6H, EGF-SRT, TNF $\alpha$ -SRT and CAHII-SRT-6H in Table 1, correspondingly) are shown.

equipped with a SrtA recognition site (LPETG) immediately following their natural C-terminal sequences, we have observed widely differing results, ranging from zero conjugate yields for CAHII to 90+% yields for EGF, with TNF $\alpha$  showing intermediate and rather poor yields. This was consistently observed with various incoming nucleophilic substrates, suggesting that some features of the protein substrates themselves are the main culprits. Another class of small, stable proteins known to be generally amenable for highly efficient C-terminal sortagging when equipped with an SrtA recognition site is camelid VHVs (nanobodies). While no experiments with VHVs are reported in this paper, we have included a VHH example (nanobody 7D12 against human EGF receptor<sup>16</sup>) in our structural comparison (Table 1 and Fig. 1). Both our laboratory<sup>15</sup> and others<sup>17</sup> have recently reported sortagging data for 6 different VHVs, including 7D12, using several biotin-containing nucleophilic substrates similar or identical to the substrates used in the present work. These sets of data rank nanobodies as an


example of a very efficient protein acceptor type for our comparison purposes.

The most probable adverse SML efficiency factor selected for further investigations at this point in our study was the poor steric availability of a protein substrate C-terminus for sortase. Indeed, the beneficial effect of distancing SrtA recognition sites from the protein globule by introducing amino acid spacers was already reported as early as a decade ago in a number of research papers,<sup>18–22</sup> as well as in general methodology publications,<sup>23,24</sup> both for the C-terminal and N-terminal SML reactions. While this concept *per se* is not novel, we were curious to assess this structural factor in a comparison study using several protein substrates in combination with a large set of synthetic amine nucleophiles with varying physicochemical properties and attached payloads. In addition, the use of appropriate molecular modelling for *a priori* protein structure evaluation with regard to the necessity of spacer introductions might make the strategic planning of SML projects less empirical.

It is known that both the N- and C-termini of folded proteins have a strong tendency to be located on the solvent exposed protein surface.<sup>25,26</sup> This does not, in itself, ensure their unrestricted steric availability to a polypeptide-modifying enzyme like sortase. Visual analysis of the available three-dimensional structures for EGF, TNF $\alpha$ , CAHII and VHH 7D12 (Protein Data Base files 2KV4, 1TNF, 1CA3, and 4KR correspondingly) provided an immediate indication that the steric availability of the C-terminal SrtA recognition site LPETG to sortase is likely to be the reason for their differential reactivity. Indeed, the crystal structures of the best SrtA substrates, EGF and VHH 7D12, show long, unstructured and solvent-exposed C-terminal tails protruding out from the tightly folded globular cores of these small proteins. In contrast, the structure of TNF $\alpha$ , a poor SrtA substrate, reveals that the protein C-termini are essentially hidden by the surrounding funnel-shaped depression formed by TNF $\alpha$  subunits forming a soluble homotrimer. In the case of CAHII, its C-terminus, while not substantially distanced from the protein globule, does not obviously appear to be sterically restrained (Fig. 1). However, our *in silico* modelling of the initial LPETG-containing CAHII protein construct indicated that molecular docking of the SrtA recognition site into the active site of the enzyme is energetically unfavourable. On the other hand, the introduction of the 10 amino acids long 2xG4S spacer between the native C-terminus of the CAHII and LPETG motifs dramatically improved the free energy minimization in this binding event (Fig. 2).

Encouraged by these observations, we have designed the modified protein expression constructs for both TNF $\alpha$  and CAHII with peptide spacer extensions between the proteins and the SrtA site. For both proteins, we have utilized a flexible unstructured linker GGGGSGGGGS (2xG4S)<sup>27</sup> that is commonly used in recombinant protein designs. This extension linker was successfully used by other groups to increase sortagging efficiency for various proteins.<sup>19,20,22,24,25</sup> For the case of CAHII, an additional construct with a much longer rigid PAS type linker<sup>28</sup> was also used for comparison. Amino acid sequences of the C-terminal variants for all 4 proteins are shown in Table 1.





**Fig. 2** PyMOL visualization of docking of the C-terminus of the CAHII-GS-SRT-6H construct in the active site of the SrtA enzyme. (A) Side view of the ClusPro Protein-Protein docking model between SrtA and the I-TASSER model of human carbonic anhydrase II (Sortase-hCAHII-2GS-SRT-6H). (B) Front view of the ClusPro Protein-Protein docking model between Sortase and the C-terminus of the I-TASSER model of hCAHII-2GS-SRT-6H. The C-terminus includes the 2xG4S linker (green), the Sortase recognition site LPETG (red), and a His-tag (yellow). Sulphur atom of the thioester intermediate forming Cys184 in the SrtA active site is coloured yellow.

In order to investigate the interplay between the properties of the acceptor proteins and incoming nucleophiles in SrtA-mediated reactions, we have decided to test the 6 resulting model proteins in combination with a set of nucleophilic substrates containing the same useful payload (biotin) attached to the varying connector amino linkers. In our recent publication,<sup>15</sup> we have screened a set of 452 unidirectionally protected diamines to identify the optimal amino linker prototypes for sortagging reactions. Here, we have selected 10 custom-synthesized biotin derivatives incorporating some of the best amino linkers discovered by us,<sup>15</sup> as well as 5 commercially available biotin derivatives used for bioconjugations *via* an amino group (Fig. 3), for comparison-testing in sortagging reactions. The amino linker chains in this compound set comprise several chemotypes – aminomethyl pyridine, aminomethyl phenyl, aminomethyl cyclobutane, aminomethyl azetidine, linear aliphatic and polyethylene glycol amines and, based on our prior data, were expected to exhibit a broad range of conjugation efficiencies. One of the derivatives, compound **15** (Biotin) containing the totally unreactive  $\alpha$ -carbon branched primary amino group<sup>13,15</sup> was included as a negative control in the sortagging experiments. To explore the effect of the distal part of the nucleophilic substrate on the sortagging efficiency, two derivatives of the macrocyclic chelator DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) commonly used in bioconjugations were also included (Fig. 3, compounds **16** and **17**). These compounds contained the same or similar amino linkers but a bulkier and strongly negatively charged payload moiety as compared to their closest biotin-derived counterparts (Fig. 3, compounds **8**, **11** correspondingly). The resulting matrix of acceptor-nucleophile pairs was tested in Sortase A reactions performed under the conditions favoring incomplete ligations for suboptimal pairs (0.5 mM nucleophile concentrations, 5:1 nucleophile substrate to protein ratio), to allow a more distinct relative efficiency ranking. We have also performed the same set of experiments at a

two-fold higher (1 mM) nucleophile concentration and a nucleophile-to-protein ratio (10:1). This data set (see Table S1, ESI<sup>†</sup>) was not used for the comparative efficiency analysis, with the exception for pairwise comparisons of DOTA derivatives (**16** and **17**) and their biotin counterparts (**8** and **11**) as shown in Fig. 5B, since the yields for many reactions were in the 90–100% range. Outcomes of the reactions were quantitatively compared after the mass-spectrometric analysis of the reaction mixtures and identification of the reaction products and by-products, as well as unreacted acceptor proteins, following the previously described methodology.<sup>15</sup> As expected, introduction of spacers between the natural C-termini of both proteins and the SrtA recognition site led to dramatic increases in their ability to be modified by SrtA using all tested substrates (Fig. 4 and Table S1, ESI<sup>†</sup>). Insertion of the 10 amino acid residues long flexible 2xG4S linker was sufficient to impart this property to the acceptor proteins while the 10-fold longer proline-rich PAS linker did not provide any advantage over 2xG4S, if not the opposite (Fig. 4).

The general concept of our study was to explore molecular features of the SML components with regard to their role in achieving the optimal productivity of sortagging, using a sizeable matrix of diverse protein acceptors and non-peptidic amino linker-cargo molecules.

## Discussion

### Structural modelling of the acceptor protein substrates

The I-TASSER online service (<https://zhanggroup.org/I-TASSER>)<sup>29–31</sup> was used to model the structures of the recombinant proteins. This tool allows for protein modeling by leveraging known structures that are partially identical or homologous to the target protein, as published in the RCSB Protein Data Bank (<https://www.rcsb.org/>).<sup>32</sup> A useful feature of I-TASSER is its ability to incorporate amino acid sequences with unknown structures into molecules with established structures or their structural homologs. These additional sequences are modeled based on their intrinsic physical properties, which are determined by their primary structure and influenced by the physical parameters of the known structures within the molecular complex. Using I-TASSER, we were able to append the Sortase A recognition tag LPETG to the C-termini of the known protein structures. The modeling also included the associated amino acid sequences, peptide spacers and 6xHis affinity purification tags, where applicable. Using I-TASSER, we predicted the structures of the following recombinant protein variants: camelid VHH against human EGF receptor (VHH\_7D12-SRT-6H); human carbonic anhydrase type II variants CAHII-SRT-6H, CAHII-2GS-SRT-6H and CAHII-PAS-SRT-6H; human epidermal growth factor (EGF-SRT); and human tumour necrosis factor alpha variants TNF $\alpha$ -SRT and TNF $\alpha$ -GS-SRT. The modeled protein structures were visualized using the PyMOL software (DeLano Scientific LLC). For all the structures mentioned above, except for the TNF $\alpha$ -SRT protein, steric accessibility of the Sortase A recognition tag (LPETG) was apparent (Fig. 1),







Fig. 3 Structures of the amino linker equipped derivatives of biotin (compounds 1–15, arranged in the order of decreasing SML efficiency based on composite product yields with 4 protein acceptors) and DOTA (16, 17) used in this work.

explaining the high sortagging efficiency of both EGF-SRT and VHH 7D12 proteins. However, this primary assessment contrasted with our experimental results showing no SrtA-mediated enzymatic reaction with the CAHII-SRT-6H protein. To investigate this discrepancy, we conducted molecular docking of *S. aureus* Sortase A (PDB structure 1T2W) with CAHII-SRT-6H using the ClusPro Protein–Protein Docking web server (<https://cluspro.org/>).<sup>33–36</sup> As a positive control, we also performed

docking for the Sortase A–CAHII-2GS-SRT-6H complex (Fig. 2). We found that SrtA forms a specific complex<sup>2</sup> with CAHII-2GS-SRT-6H, whereas no such complex was formed with CAHII-SRT-6H. The docking parameters of the Sortase A–CAHII-2GS-SRT-6H and Sortase A–CAHII-SRT-6H complexes differ significantly. For the Sortase A–CAHII-2GS-SRT-6H complex, the parameters are as follows: balanced docking, Cluster 0, 115 members, with a representative center weighted



**Fig. 4** Comparative visualization of conjugate product yields' distribution for all the tested combinations of the 6 acceptor proteins (CAHII highlighted in red, TNF $\alpha$  in blue, and EGF in green) and 14 incoming biotin-containing substrates (**1–14**), excluding the non-reactive biocytin (**15**) control.

score of  $-508.6$  and a representative lowest energy weighted score of  $-620.5$ . In contrast, for the Sortase A-CAHII-SRT-6H complex, the parameters are as follows: balanced docking, Cluster 0, 66 members, with a representative center weighted score of  $-137.7$  and a representative lowest energy weighted score of  $-170.5$ . These differences suggest that the probability of forming the Sortase A-CAHII-SRT-6H complex is low, which likely explains the lack of activity observed in the Sortase reaction for CAHII-SRT-6H. Visualization of the superposition of LPETG motifs in the sortase active site comparing our CAHII-2GS-SRT-6H model with the published data on the peptide substrate interactions with SrtA,<sup>37</sup> which shows good matching, is included in the ESI<sup>†</sup> (Fig. S3).

Thus, prior to planning sortagging experiments, it is advisable to assess the 3D structures of the proteins of interest, if available, for the possible C-terminal steric accessibility constraints. In cases where structural predictions alone might be inconclusive, we recommend complementing I-TASSER modeling with molecular docking of the predicted structures with Sortase using the ClusPro service. Alternatively, a flexible linker, such as 2xG4S, can be introduced before the SrtA recognition site as a precautionary measure, in case the relevant structural information does not exist or is not unambiguously interpretable.


#### pK<sub>a</sub> and nucleophilicity of incoming substrates

Acylation of amines in aqueous buffers requires a portion of the amine to be in a non-protonated state, which participates in the acylation reaction. Consequently, an increase in the fraction of non-protonated amine increases the acylation rate. The larger degree of deprotonation of the primary amino group on the incoming substrate would make it a more reactive nucleophile in sortagging reactions. A comprehensive compilation study of the experimentally measured pK<sub>a</sub> values for ionizable groups in

folded proteins<sup>38</sup> reports the average pK<sub>a</sub> (negative logarithm of the acid dissociation constant) of the protonated amino group of their N-termini as 7.7 (range of 6.8–9.1 on 16 measurements), while the more recent database<sup>39</sup> provides the average pK<sub>a</sub> as 7.64 (range of 6.91–9.14 on 22 measurements). The same parameter measured by several laboratories for various model peptides, including oligo-glycine peptides, is in the narrow range of 7.5–8.1.<sup>40</sup> Theoretically, exceeding the pK<sub>a</sub> of a reactive amino group of a substrate by one pH unit would lead to deprotonation of 90% of the amino group, while exceeding the pK<sub>a</sub> by two pH units would bring this number to 99%. This allows us to conclude that conducting sortagging reactions at the often-used pH 9 is a reasonable choice for the incoming nucleophiles which are either N-Gly containing proteins or N-Gly peptide-based substrates. The choice of this pH for the reaction buffer is essentially a trade-off between decreasing the positive charge on the nucleophilic primary amino group by increasing the reaction buffer pH, and at the same time not deviating too drastically from the optimal pH for the enzymatic activity of SrtA – which is around 8 and drops steeply above pH 9.<sup>41</sup>

For the synthetic non-peptidic amine substrates, there is a potential possibility of designing improved amino group-containing linkers with depressed pK<sub>a</sub> values hence better reactivity, as long as the associated structural modifications do not affect the substrate recognition by the SrtA enzyme (and hopefully even improve it). Such an accomplishment could enhance reaction yields, as well as reduce the consumption of the enzyme and substrate. At a constant pH, the fraction of non-protonated amine increases if the pK<sub>a</sub> of the protonated amine decreases, which can be achieved by introducing adjacent electronegative groups. However, electronegative groups also decrease the acylation reaction rate constant by withdrawing electron density from the nucleophilic centre, making it less reactive. Thus, electronegative substituents exert two opposing effects, and the predominance of one will either facilitate or hinder amine acetylation. A well-known example of acylation being facilitated by an electronegative substituent is the pH-dependent selectivity in acylation reactions for the  $\alpha$ -amino group at the N-terminus *versus* the  $\varepsilon$ -amino groups of lysine residues in proteins.<sup>42</sup> Since the use of chemically diverse non-peptidic incoming nucleophiles efficiently mimicking the conventional (oligo)glycine substrates is a developing trend in the practice of sortagging, studies of structure–activity relationships in such molecules are of great interest. Since the experimentally determined pK<sub>a</sub> values for the biotin derivatives used in this study were not available, we have calculated the corresponding pK<sub>a</sub> for their primary amino groups using four well-validated software tools of both the corporate (Chemaxon, ACD/Labs, Schrodinger) and academic (MolGpka server<sup>43</sup>) origin. The reliable computation of ionization properties for chemical compounds is still a challenging task,<sup>44</sup> and there is significant variability in pK values calculated using a variety of reported methods. Therefore, we have used arithmetic means of the four algorithmically different pK<sub>a</sub> calculations performed using reputable software tools for evaluating the correlation of pK<sub>a</sub> values with the observed reactivity of the compounds (Fig. 5A).





**Fig. 5** (A) Composite reaction yields (%) (left scale) for 4 protein acceptors, excluding the non-reactive proteins, and 14 biotin derivatives (**1-14**), excluding the non-reactive biocytin (**15**). The stacked bars (EGF – grey, TNF $\alpha$ -GS-SRT – black, CAHII-GS-SRT-6H – light grey, CAHII-PAS-SRT-6H – brick pattern) are sorted left to right in the order of decreasing composite yield. The line connecting mean  $pK_a$  values (right scale) for each substrate is overlaid over the bar graph. Brackets connect the compounds for pairwise comparisons. (B) Same graphical representation as in (A) for comparing two DOTA derivatives (**16** and **17**) with their corresponding biotin counterparts (**8** and **11**). Yields correspond to SML reactions done at 0.5 mM (panel A) or 1 mM (panel B) nucleophile concentrations.

Complete numerical data used in this graph can be found in the ESI† (Table S1). Despite the intrinsic imprecision of the plotted product yield *versus*  $pK_a$  data, the expected trend of inverse dependency between the  $pK_a$  values, reflecting the nucleophilicity of the compounds, and their sortagging efficiency, expressed as composite product yields with four different protein acceptors, is apparent.

Interestingly, despite the fact that the 10 custom-synthesized biotin derivatives (compounds **1-7**, **9**, **10**, and **12**) containing the most efficient amino linkers were selected as a result of a comparative sortagging screen of 452 diverse model mono-protected diamines,<sup>15</sup> their computed amino group  $pK_a$  values are close to the experimentally determined  $pK_a$  for N-terminal glycines in peptidic substrates.<sup>37-39</sup> This creates a potential for further improvement in the nucleophilicity of the substrates, *e.g.* *via* introduction of electrophilic substituents in the vicinity of the reactive amino group. Since the correlation of amine basicity and nucleophilicity is not perfect and the predictability of a substituent effect on both the nucleophilicity and substrate-enzyme recognition is limited, such an endeavor would clearly require mostly a trial-and-error molecular screening effort.

### Structural features of nucleophilic substrates

In addition to nucleophilicity, structural features of SrtA substrates determining their interaction with the enzyme must be also among the factors affecting their reaction efficiency. Indeed, the compounds **7** and **12**, which are stereoisomers of each other and therefore have identical  $pK_a$  values and nucleophilicity, show distinctly different sortagging efficiency

(Fig. 5A). In this case, the conformation-modifying chiral center is located in the immediate vicinity of the active site of SrtA, and the direct substrate-enzyme recognition is apparently affected. To explore this aspect further, we have included two commercially available amino linked derivatives of DOTA, a chelator used in bioconjugations for producing targeted imaging and therapeutic radiopharmaceuticals or MRI contrast agents, in our panel of sortagging substrates. DOTA is a bulky macrocyclic compound decorated with 3 or 4 free carboxylic groups in the two selected derivatives, which imparts a strong negative charge to the DOTA payload moiety in contrast to a smaller and non-charged biotin cargo. DOTA-derived compound **16** and biotin-derived compound **8** contain the same SrtA active site-proximal ethylenediamine linker, have almost identical calculated  $pK_a$  values for the nucleophilic amino group, as well as approximately the same overall linker distance from the nucleophilic amino group to the payload attachment point. However, the DOTA derivative **16** shows much lower conjugation yields than **8** with all 4 acceptor proteins (Fig. 5B). On the other side, the second DOTA derivative, compound **17**, with a much longer linker, shows substantially improved conjugation yields – close to those of the biotin derivative **11** with a similar polyethylene glycol linker (Fig. 3). Again, these two compounds also have very close  $pK_a$  values of their amino groups. These pairwise comparisons clearly suggest a detrimental effect of the DOTA moiety, contrary to biotin, on the substrate interaction with the enzyme, which is relieved by increasing the length of the separating spacer. The subjects of structure and nucleophilicity of noncanonical attacking nucleophiles with regard to their performance in SML were raised by



others;<sup>11,12,14</sup> the goal of this and our preceding study<sup>15</sup> was to gain deeper insight into the issue.

A potential caveat in our conclusions may stem from the fact that two out of the 17 tested substrates (compounds **13**, **14**) were procured as trifluoroacetic acid (TFA) salts, while the rest were supplied as either free bases or hydrochloride salts. Since trifluoroacetate was reported to interfere with biological activities in some cell-based and biochemical assays,<sup>45</sup> we have checked whether TFA had an inhibitory effect on Sortase A, which may have potentially led to reaction efficiency underestimation for the corresponding nucleophiles. This was tested by running control sortagging reactions with TNF $\alpha$ -GS-SRT and CAHII-GS-SRT-6H and compound **11** (biotin ethylenediamine) in parallel in the presence or absence of 0.5 mM of sodium trifluoroacetate. No inhibition of SrtA by TFA was detected in these assays (Table S2, ESI $\dagger$ ). Another potential issue is a solubility limit below 0.5 mM, which might compromise the reactivity data for some biotin derivatives. Biotin itself is sufficiently well soluble in both DMSO and aqueous buffers. However, decoration of the biotin moiety by amino linkers containing alkyl, aryl or polyethylene glycol chains of various lengths could potentially decrease the solubility of some derivatives. The solubility of biotin cadaverine (compound **13**), likely one of the most hydrophobic compounds from the tested set also showing inferior efficiency in sortagging, is reported to be around 5 mM in aqueous buffers by some reagent vendors. Our visual microscopic examination of 0.5–1 mM solutions of compound **13** in the aqueous sortase reaction buffer, which additionally contains 5% of solubility enhancing DMSO, also did not show any signs of insolubility.

It is worth noting that for compounds **1**–**10** (Fig. 3), which are all biotin derivatives decorated with the most efficient amino linkers discovered by us previously in an MS-based SML screen of a model *tert*-butyloxycarbonyl (Boc) group mono-protected diamine library,<sup>15</sup> most of the observed conjugate product yields fall into the 90–100% range for the effective protein acceptors, especially for the experiments run at 1:10 acceptor–substrate ratio (Table S1 and Fig. 5A, ESI $\dagger$ ). The observed high sortagging yields could result from either the high reaction rates, reaction irreversibility, or both. In-depth mechanistic study of the many acceptor–nucleophile combinations explored here is beyond the focus and the scope of this work and must be the subject of a separate investigation. However, the selected time course experiments on TNF $\alpha$ -GS-SRT and compounds **1** and **7** (see Fig. S4, ESI $\dagger$ ) indicate both the fast reaction kinetics and probable irreversibility of SML for these substrate–nucleophile pairs. The latter characteristic is not an unexpected finding for the sortagging of a synthetic non-peptidic molecule to a protein, which *a priori* is likely to lead to the formation of an unnatural amide bond product which can no longer be attacked by sortase. Many inventive approaches to imparting irreversibility to SML by protein acceptor and nucleophile engineering, as well as reaction setup modifications, including those employing the formation of unnatural conjugated bonds, are referenced in several comprehensive literature reviews.<sup>6,8,9</sup> The use of optimized surrogate non-peptidic

linkers may well become the preferred way of attaching a useful chemical cargo to protein C-termini due to its simplicity and consistently achievable high yields. As graphically illustrated in Fig. 4 and 5, the relative reactivity ranking of the 14 biotin derivatives was very similar for all the tested proteins, indicating the absence of any specific interactivity within the acceptor–substrate pairs, which could have modulated the efficiency of sortagging. These results imply a general suitability and effectiveness of these well performing non-peptidic linkers for different proteins and cargo molecule types.

## Materials and methods

### Reagents

Compounds **16** – NH<sub>2</sub>-DOTA-GA (Cat. #C116) and **17** – NH<sub>2</sub>-PEG4-DOTA (Cat. #C125) were purchased at Chematech. Five biotin derivatives – biotin ethylenediamine, hydrochloride (Cat. #90075); biotin cadaverine, trifluoroacetate (Cat. #90063); biocytin ( $\epsilon$ -biotinyl-L-lysine) (Cat. #90055); biotin-PEO<sub>2</sub>-PPO<sub>2</sub>-amine, trifluoroacetate salt (Cat. #90078) and biotin-PEO<sub>3</sub>-amine (Cat. #90067) were all from Biotium. Ni-The NTA affinity sorbent was from G-Biosciences. All standard biochemicals, including Tris, isopropyl- $\beta$ -D-galactopyranoside (IPTG), 2-mercaptoethanol (2-ME), dithiothreitol (DTT), ampicillin (Amp), dimethyl sulfoxide (DMSO), bacterial growth media components and mineral salts were purchased from either MilliporeSigma or Bio Basic. Ten additional biotin derivatives (compounds **1**–**7** and **9**, **10**, and **12**, Fig. 1) were custom synthesized by enamine; the corresponding synthetic and analytical data can be found in the ESI, $\dagger$  except for the previously described compounds **1**, **3**, **4**, **5**,<sup>14</sup>

### Recombinant proteins

All recombinant proteins used in this work were produced in our laboratory according to the protocols shown below to a purity level of  $\geq 95\%$ , as controlled by SDS-PAGE and QTOF LC/MS (Fig. S1 and S2, ESI $\dagger$ ). Expression and purification of SrtA7M, the heptamutant Sortase A version<sup>46,47</sup> used in this work, was described before.<sup>15</sup>

**Epidermal growth factor (EGF).** The expression constructs for human epidermal growth factor (EGF) were produced at GenScript by cloning the synthetic NdeI-BamHI DNA cassette encoding the *E. coli* codon-optimized sequence of mature EGF (53 amino acid residues, PDB 1IVO-C, D) fused with 6xHis-tagged *S. cerevisiae* SMT3 (SUMO) at its N-terminus and SrtA recognition motif LPETGG at its C-terminus into the pET21a(+) expression vector (Novagen). Expression and purification procedures were based on the published protocols.<sup>48,49</sup> *E. coli* strain Rosetta-Gami 2 (DE3) (Sigma-Aldrich/Novagen) was transformed with the expression plasmid and a single colony was picked to inoculate 20 mL of LB media with 100  $\mu$ g mL<sup>−1</sup> ampicillin (Amp) and grow overnight at 37 °C on an orbital shaker (250 rpm). The overnight culture was inoculated at the ratio of 1:100 to 0.7 L of LB medium with 100  $\mu$ g mL<sup>−1</sup> Amp. The culture was then grown at 37 °C on an orbital shaker (180 rpm). When the OD<sub>600</sub> reached  $\sim 0.8$ , the shaker



temperature was switched to 18 °C, and the protein expression was induced by adding IPTG to 1 mM concentration. The culture was grown at 18 °C with shaking at 200 rpm for 18–20 hours, then the cells were harvested by centrifugation at 6000 g, 4 °C for 10 min. The cell pellet (10 g) was resuspended in 50 mL of buffer A (25 mM Tris HCl, 300 mM NaCl, 10 mM imidazole, 5% glycerol, 5 mM 2-mercaptoethanol (2-ME), pH 7.5) containing 1 mM PMSF (5 mL g<sup>-1</sup> cell pellet) and sonicated for 5 min on ice in 50–50 pulse mode with 70% amplitude using a Branson SFX250 250 ultrasonic cell disintegrator with 1/2" horn. A few crystals of DNase I were added to the lysate before centrifuging it at 20 000g at 4 °C for 20 min. The collected supernatant was mixed with the Ni-NTA affinity sorbent (9 mL) pre-equilibrated with buffer A and then incubated for 2 h at 4 °C on a rotator. The slurry was transferred to a disposable chromatography column and washed successively with buffer A supplemented with 0.1% Triton X-100 (5 bed volumes, BV), buffer A (9 BV) and then with buffer A containing increasing concentrations of imidazole – 20 mM (2 BV), 40 mM (2 BV) and 60 mM (1 BV). The bound protein was eluted from the column with buffer A supplemented with 250 mM imidazole (3 BV). Collected fractions were analysed using 12% SDS-PAGE and combined as appropriate. The elution buffer was exchanged for buffer B (50 mM Tris-HCl, 150 mM NaCl, 5% glycerol, 2-ME pH 7.5) using desalting Sephadex G25M PD-10 columns (Cytiva). In the next step, the fusion protein was digested by SUMO-specific Ulp1 protease (Ulp1: protein = 1:30 by weight) at 30 °C on a rotator for 1.5 hours. To separate His-tagged SUMO and Ulp1 from the cleaved-off EGF, the reaction mix was supplied with Ni-NTA sorbent (5 mL) and incubated on a rotator for 20 min at room temperature, then loaded onto a disposable column and washed with buffer C (50 mM Tris HCl, 150 mM NaCl, pH 7.5, 4 BV), buffer C + 20 mM imidazole (2 BV), and buffer C + 250 mM imidazole. 18% SDS-PAGE was run to analyse the fractions stored at 4 °C before the subsequent concentration (Vivaspin Turbo 4, 3 kDa MWCO, Sartorius). The final polishing chromatography was run on an FPLC Superdex 200 16/600 column at a flow rate of 0.8 mL min<sup>-1</sup> in 25 mM Tris-HCl, pH 7.5, and 200 mM NaCl. The collected fractions were analysed on 18% SDS-PAGE, appropriately combined, concentrated and frozen in liquid nitrogen. Typical yields of the purified EGF-LPETGG were 1–2 mg L<sup>-1</sup> of bacterial culture. Full verification of the protein sequence indicating formation of 3 internal disulfide bonds was done by LC/MS-QTOF. The biological activity of EGF-LPETGG was tested in the A431 cell line proliferation assay and found to be consistent with the literature data<sup>50,51</sup> (data not shown).

**Tumour necrosis factor alpha (TNF $\alpha$ ).** Two expression constructs for human tumour necrosis factor alpha (TNF $\alpha$ ) were produced at GenScript by cloning the synthetic NdeI-BamHI DNA cassettes encoding the *E. coli* codon-optimized sequence of mature TNF $\alpha$  (157 amino acid residues, GenBank AAC03542) fused with 6xHis-tagged *S. cerevisiae* SMT3 (SUMO) at their N-termini and SrtA recognition motif LPETGG (with or without the preceding 2xG4S linker) at its C-terminus into the pET21a(+) expression vector (Novagen). Both versions of TNF $\alpha$ ,

differing only by the presence of the GGGGSGGGGS spacer, were produced in *E. coli* and purified using the same protocol. In a typical experiment, *E. coli* BL21 (DE3) (Novagen) cells transformed with the corresponding TNF $\alpha$  construct were grown in a shaker at 37 °C in 5 L of LB medium with 100  $\mu$ g mL<sup>-1</sup> ampicillin (Amp). When the OD600 reached ~0.8, the shaker temperature was switched to 18 °C, and protein expression was induced by adding IPTG at a 0.5 mM concentration. The culture was grown at 18 °C for 18–20 hours, then the cells were harvested by centrifugation at 6000 g, 4 °C, 10 min. Approximately 20 g of wet pellet was resuspended in 200 mL of lysis buffer (20 mM Tris HCl, pH 8.0, 300 mM NaCl, 10 mM imidazole, 5 mM 2-ME, 10% glycerol, and 1 mM PMSF). The suspension was sonicated on ice (2 × 3 min) in pulsed mode using the Branson Sonifier 250 with a 1/2-inch disruptor horn, then supplied with DNase A at 10  $\mu$ g mL<sup>-1</sup> and incubated on ice for 15 min. The lysate was clarified by centrifugation at 48 000g for 30 min and the supernatant was filtered through a 0.45 nylon membrane. Ni-NTA affinity resin equilibrated with lysis buffer was added to the supernatant (~1 mL of resin per 10–20 mg of protein) and incubated for 1 h at +4 °C on a rotator. The resin was loaded onto a disposable column and washed sequentially with 10 column volumes of lysis buffer and 6 column volumes each of the same buffer containing 20 mM and 35 mM imidazole. Purified protein was eluted with 4 column volumes of elution buffer (20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 250 mM imidazole, 5 mM 2-ME, 10% glycerol). After the buffer exchange on the PD-10 gel-filtration column (GE Healthcare), the SUMO-tag was cleaved off from the purified fusion protein by adding 6xHis-tagged ULP1 protease (at a ratio of 12  $\mu$ g of ULP1 protease per 1 mg of 6xHis-SUMO-TNF $\alpha$ ) in 20 mM Tris-HCl pH 8.0, 150 mM NaCl, and 2 mM DTT for 1 h at 30 °C. Upon the completion of the cleavage, Ni-NTA resin equilibrated with the same buffer was added to the proteolysis mixture (~1 mL of resin per 10–20 mg of protein), incubated with rotation for 1 h and separated by gravity flow. The flow-through was collected, and fractions were analysed by SDS-PAGE and concentrated to 4–5 mg mL<sup>-1</sup> protein using a centrifugal concentrator with 10 000 MW cut-off (Amicon Ultra). The final yields of the TNF $\alpha$  proteins were ~15 mg L<sup>-1</sup> of the bacterial culture.

**Carbonic anhydrase type II (CAHII).** Three versions of human carbonic anhydrase type II (CAHII), differing by the spacers in their C-terminal parts, were produced in *E. coli* and purified following the same protocol. The expression plasmids were produced at GenScript by cloning the synthetic NdeI-XbaI DNA cassettes encoding *E. coli* codon usage-optimized open reading frames of CAHII (260 amino acids, UniProt P00918, CAH2\_HUMAN) C-terminally fused to SrtA site LPETG and 6xHis tag with or without the interposed linkers (Table 1) into the pET21a(+) expression vector (Novagen). Proteins were expressed in *Escherichia coli* BL21(DE3) pLysS (Novagen). Bacteria were grown overnight at 37 °C in 20 mL of LB medium at 100  $\mu$ g mL<sup>-1</sup> Amp, then diluted to 250 mL of the fresh medium supplemented with 0.4 mM zinc chloride and grown at 37 °C, while being shaken at 180 rpm until OD600 reached 0.4.



Induction was performed by switching the shaker temperature to 18 °C and adding IPTG to a final concentration of 1 mM at OD600 ~ 0.75. Following expression for 20 h, the cultures were centrifuged at 6000g for 20 min, and the pellets were frozen in liquid nitrogen and stored at –80 °C. The pellets were resuspended in lysis buffer (50 mM NaH<sub>2</sub>PO<sub>4</sub>, pH 7.5; 200 mM NaCl; 5 mM 2-ME; 1 mM PMSF) with a few crystals of DNase I added at 10 mL g<sup>−1</sup> of cells and sonicated for 3–5 minutes on ice in pulse mode using the Bransonic Sonifier 250. Cell lysates were centrifuged at 48 000g and 4 °C for 40 min, the supernatant was collected and filtered through 0.2 µm syringe filters prior to chromatography. Proteins were purified using nickel affinity chromatography using gravity-flow columns with a bed volume of 7 mL. The column was washed sequentially with lysis buffer containing 0, 20, 40 and 60 mM imidazole, 5 column volumes of each. Elution was done with a buffer containing 250 mM imidazole (3 column volumes). Protein fractions were analysed using SDS-PAGE and dialyzed against 25 mM Tris-HCl, pH 7.5, and 200 mM NaCl overnight at +4 °C. Dialyzed protein was concentrated to ~5 mg mL<sup>−1</sup> using Sartorius Turbo15 30 000 MWCO centrifugal concentrators, aliquoted and snap-frozen in liquid nitrogen. The yields of the proteins were in the range of 10–15 mg L<sup>−1</sup> of bacterial culture. N-terminal methionine residue was post-translationally removed by *E. coli* Met aminopeptidase in all three versions of CAHII as indicated by LC/TOF-MS.

### Sortagging efficiency comparisons for the protein acceptor-nucleophile pairs

**Sortase A reactions.** Sortase reactions and quantitative mass-spectrometric assessment of the results were performed as described before.<sup>15</sup> Stock solutions of the biotin derivatives were prepared in dry dimethyl sulfoxide (DMSO) at 20 mM concentrations and stored frozen in hermetically sealed polypropylene vials. Aliquots of the compound stocks were dispensed in 384-well microplates using the Labcyte Echo 550 acoustic liquid handler at 500 nL solution per well for the reactions with 1 mM substrate concentration. If reactions were run at 0.5 mM substrate, then 250 nL of the stock solution plus 250 nL DMSO were dispensed. To start sortagging reactions, 9.5 µL volumes of the master mix containing 10 µM SrtA7M enzyme and 100 µM of one of the 6 tested protein variants in 50 mM Tris-HCl, pH 9.0, and 150 mM NaCl buffer were dispensed to all wells using a Thermo Scientific Multidrop Combi nL liquid handler. The plates were sealed with a microplate cover film, spun at 2000 rpm for 1–2 min and incubated on a shaker for 24 h at 4 °C and 400 rpm.

**Mass-spectrometry.** To terminate the sortase reactions and prepare the samples for LC/MS analysis, 40 µL of 0.1% formic acid in water was added to each well using a Multidrop Combi reagent dispenser (ThermoFisher Scientific), plates were closed with a pierceable aluminium seal, briefly centrifuged, and placed in cooled Agilent G1367B autosampler. LC/MS analysis was performed using an Agilent 1200 series HPLC system in line with an Agilent 6550 iFunnel QTOF mass spectrometer with a Dual AJS Electrospray ion source. Chromatography of sample aliquots (5 µL injections) was done on Agilent Zorbax

300SB-C3 5 µM cartridges 4.6 × 12.5 mm at 20 °C for 10 min according to the pre-developed gradient program. Deconvolution of the MS data was using the Agilent MassHunter Bioconfirm 10.0 software. Atomic mass values, as well as the peak heights, of biomolecule peaks were exported to a Microsoft Excel file and further data processing was done in Excel. The biomolecules were identified based on the computed molecular masses of the proteins, and the expected products of their reaction with each ligand or hydrolytic side-products. Molecular weight values of the proteins/side-products were matching the following: EGF-Srt (6770/6656 Da), TNFα-SRT (17 794/17 680 Da) TNFα-GS-SRT (18 538/18 422 Da), CAH-SRT-6H (30 435/29 555 Da), CAH-GS-SRT-6H (31 069/30 186 Da), and CAH-PAS-SRT-6H (34 570/33 688 Da). Deconvolution deviations were all within 4 Da. Detected peaks for the SrtA7M enzyme (17 722.4 Da) were excluded from further calculations. The peak height ratios for the initial protein, conjugate product and the side-product were assumed to be equal to their molar ratio. Based on this assumption, for each well the absolute peak heights (counts) for the identified molecules were normalized to their sum and the resulting values were reported as their % molar fractions. Most of the experiments were performed in singleton, based on the sufficiently high quantitative reproducibility observed in this and our previous<sup>15</sup> large-scale mass-spectrometry based study. Examples of the experimental reproducibility are shown in the ESI,† Fig. S4 and S5.

### Computational methods

**Modelling of protein structures.** The structures of the parental proteins of the recombinant variants used in this study were obtained from the RCSB Protein Data Bank (<https://www.rcsb.org/>). The I-TASSER web server (<https://zhanggroup.org/I-TASSER/>)<sup>29–31</sup> was used to model the structures of the proteins. The predicted structures were visualized using the PyMOL software (DeLano Scientific LLC, 2009). Molecular docking studies were done using the ClusPro Protein–Protein Docking (<https://cluspro.org/>)<sup>33–36</sup> online server.

**Calculations of pK<sub>a</sub> values for compounds.** Acid dissociation constant (pK<sub>a</sub>) values for the corresponding conjugate acids (ammonium cations) of the primary amino groups of the compounds used in this study were calculated using the pK<sub>a</sub> module of Marvin Sketch, ver. 23.16 (Chemaxon); Acid Dissociation Calculator, ver.12 (ACD/Labs), Epik 7 2024-1 module (Schrödinger, Inc.)<sup>52</sup> and MolGpka web server<sup>43</sup> (<https://xundrug.cn/molgpka>) using the default software settings in all cases. Most of the computational, as well as the experimentally measured, pK<sub>a</sub> values mentioned in the paper relate to a temperature of 25 °C (298 K). To minimize the inherent output variability between the different calculation algorithms, arithmetic means of the four computed values were used for assessing the reactivity-pK<sub>a</sub> correlation.

### Conclusions

We carried out a systematic study of the relative efficiency of C-terminal sortagging using a large panel of protein acceptors



and incoming non-peptidic nucleophile substrates, with the goal of elucidating the factors, specific for the acceptor-nucleophile combinations that may affect the SML reactions. We concur with the previously published research<sup>18–24</sup> implying the highly critical role of the C-termini of acceptor proteins bearing the SrtA recognition site on ligation efficiency. In agreement with the existing studies, introduction of a short peptide linker extending the sortagging site-bearing C-tail out from the sterically constrained protein markedly augments the SML efficiency. We have developed a structural protein assessment and modelling procedure aimed at rationalizing the planning of SML experiments in this regard. Other factors, the role of which are apparent from our results, are the basicity (nucleophilicity) of the attacking amino group of the substrate in combination with the structural recognition of the adjacent linker part of the molecule by the enzyme, including the reactive amino group-proximal stereochemistry. An interesting avenue for further improvement in sortagging technology would be the attempt to create synthetic amino linkers with enhanced nucleophilicity and optimized enzyme-substrate interactions by introducing appropriate substituents in the vicinity of the reactive amino groups. The chemical nature of the linker-attached cargo molecules appears to be able to negatively modulate the yields as well, possibly due to the size- or charge-dependent interference with the adjacent enzyme. We hope that these practical insights will help the research community to better design and implement bioconjugation experiments using sortases.

## Abbreviations

SML	Sortase-mediated ligation
PDB	Protein Data Bank
DTT	Dithiothreitol
2-ME	2-Mercaptoethanol
PMSF	Phenylmethylsulphonyl fluoride
DMSO	Dimethyl sulfoxide
Ni-NTA	Nickel(II)-nitritotriacetic acid
Amp	Ampicillin
IPTG	Isopropyl $\beta$ -D-1-thiogalactopyranoside
MWCO	Molecular weight cut-off
SrtA	Sortase A from <i>S. aureus</i>
TFA	Trifluoroacetic acid

## Author contributions

The manuscript was written through significant contributions of all authors. All authors have given approval to the final version of the manuscript. Below, roles of each author are specified according to the CRediT (<https://credit.niso.org/>) descriptors. Conceptualization: TB, OS, SAZ; data curation: TB, OS, SAZ; formal analysis: MOD, OP; investigation: TB, DV, AP, MK, YM, ON; methodology: MOD, YM, ON; project administration: SAZ; software: MOD, OP; resources: AP, MK; supervision: EZ, OS; visualization: TB, EZ,

MOD; writing – original draft: SAZ; writing – review and editing: TB, EZ, OS, VB, SAZ.

## Data availability

The supporting data for this article was included as part of the ESI.†

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

All authors are grateful to Prof. Andrei Tolmachev for supporting this work. We would also like to thank Anton Cherednichenko for assisting with the  $pK_a$  calculations and Olga Kuchuk for valuable discussions and help with illustrations.

## References

- 1 J. F. Amacher and J. M. Antos, *Trends Biochem. Sci.*, 2024, **49**, 596–610.
- 2 U. Ilangovan, H. Ton-That, J. Iwahara, O. Schneewind and R. T. Clubb, *Proc. Natl. Acad. Sci. U. S. A.*, 2001, **98**, 6056–6061.
- 3 S. K. Mazmanian, G. Liu, H. Ton-That and O. Schneewind, *Science*, 1999, **285**, 760–763.
- 4 H. Mao, S. A. Hart, A. Schink and B. A. Pollok, *J. Am. Chem. Soc.*, 2004, **126**, 2670–2671.
- 5 N. Braga Emidio and R. W. Cheloha, *Curr. Opin. Chem. Biol.*, 2024, **80**, 102443.
- 6 Z. Zou, Y. Ji and U. Schwaneberg, *Angew. Chem., Int. Ed.*, 2024, **63**, e202310910.
- 7 E. M. Obeng, A. J. Fulcher and K. M. Wagstaff, *Biotechnol. Adv.*, 2023, **64**, 108108.
- 8 H. E. Morgan, W. B. Turnbull and M. E. Webb, *Chem. Soc. Rev.*, 2022, **51**, 4121–4145.
- 9 X. Dai, A. Boker and U. Glebe, *RSC Adv.*, 2019, **9**, 4700–4721.
- 10 N. Pishesha, J. R. Ingram and H. L. Ploegh, *Annu. Rev. Cell Dev. Biol.*, 2018, **34**, 163–188.
- 11 S. Baer, J. Nigro, M. P. Madej, R. M. Nisbet, R. Suryadinata, G. Coia, L. P. Hong, T. E. Adams, C. C. Williams and S. D. Nuttall, *Org. Biomol. Chem.*, 2014, **12**, 2675–2685.
- 12 J. E. Glasgow, M. L. Salit and J. R. Cochran, *J. Am. Chem. Soc.*, 2016, **138**, 7496–7499.
- 13 Z. Zou, M. Nöth, F. Jakob and U. Schwaneberg, *Bioconjugate Chem.*, 2020, **31**, 2476–2481.
- 14 E. M. Obeng, D. L. Steer, A. Fulcher and K. M. Wagstaff, *Bioconjugate Chem.*, 2023, **34**, 1667–1678.
- 15 T. Bondarchuk, D. Vaskiv, E. Zhuravel, O. Shyshlyk, Y. Hrynyshyn, O. Nedialko, O. Pokholenko, A. Pohribna, O. Kuchuk, V. Brovarets and S. Zozulya, *Bioconjugate Chem.*, 2024, **35**, 1172–1181.

16 K. R. Schmitz, A. Bagchi, R. C. Roovers, P. M. van Bergen en Henegouwen and K. M. Ferguson, *Structure*, 2013, **21**, 1214–1224.

17 E. M. Obeng, D. L. Steer, A. J. Fulcher and K. M. Wagstaff, *Nanoscale Adv.*, 2023, **5**, 2251–2260.

18 D. J. Williamson, M. A. Fascione, M. E. Webb and W. B. Turnbull, *Angew. Chem.*, 2012, **51**, 9377–9380.

19 T. Heck, P. Pham, F. Hammes, L. Thöny-meyer and M. Richter, *Bioconjugate Chem.*, 2014, **25**, 1492–1500.

20 K. Wagner, M. J. Kwakkenbos, Y. B. Claassen, K. Maijor, M. Böhne, K. F. van der Sluijs, M. D. Witte, D. van Zoelen, L. A. Cornelissen, T. Beaumont, A. Q. Bakker, H. L. Ploegh and H. Spits, *Proc. Natl. Acad. Sci. U. S. A.*, 2014, **111**, 16820–16825.

21 Q. Chen, Q. Sun, N. M. Molino, S. Wang, E. T. Boder and W. Chen, *Chem. Commun.*, 2015, **51**, 12107–12110.

22 S. Reed, D. Brzovic, S. Takasaki, K. V. Boyko and J. M. Antos, *Bioconjugate Chem.*, 2020, **31**, 1463–1473.

23 C. P. Guimaraes, M. D. Witte, C. S. Theile, G. Bozkurt, L. Kundrat, A. E. Blom and H. L. Ploegh, *Nat. Protoc.*, 2013, **8**, 1787–1799.

24 J. M. Antos, J. Ingram, T. Fang, N. Pishesha, M. C. Truttmann and H. L. Ploegh, *Curr. Protoc. Protein Sci.*, 2017, **89**, 15.3.1–15.3.19.

25 E. Jacob and R. Unger, *Bioinformatics*, 2007, **23**, e225–e230.

26 S. Sharma and M. R. Schiller, *Crit. Rev. Biochem. Mol. Biol.*, 2019, **54**, 85–102.

27 X. Chen, J. L. Zaro and W. C. Shen, *Adv. Drug Delivery Rev.*, 2013, **65**, 1357–1369.

28 J. Breibeck and A. Skerra, *Biopolymers*, 2018, **109**, e23069.

29 J. Yang and Y. Zhang, *Nucleic Acids Res.*, 2015, **43**, W174–W181.

30 W. Zheng, C. Zhang, Y. Li, R. Pearce, E. W. Bell and Y. Zhang, *Cells Rep. Methods*, 2021, **1**, 100014.

31 X. Zhou, W. Zheng, Y. Li, R. Pearce, C. Zhang, E. W. Bell, G. Zhang and Y. Zhang, *Nat. Protoc.*, 2022, **17**, 2326–2353.

32 H. M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T. N. Bhat, H. Weissig, I. N. Shindyalov and P. E. Bourne, *Nucleic Acids Res.*, 2000, **28**, 235–242.

33 D. Kozakov, D. Beglov, T. Bohnuud, S. E. Mottarella, B. Xia, D. R. Hall and S. Vajda, *Proteins*, 2013, **81**, 2159–2166.

34 D. Kozakov, D. R. Hall, B. Xia, K. A. Porter, D. Padhorny, C. Yueh, D. Beglov and S. Vajda, *Nat. Protoc.*, 2017, **12**, 255–278.

35 I. T. Desta, K. A. Porter, B. Xia, D. Kozakov and S. Vajda, *Structure*, 2020, **28**, 1071–1081.

36 S. Vajda, C. Yueh, D. Beglov, T. Bohnuud, S. E. Mottarella, B. Xia, D. R. Hall and D. Kozakov, *Proteins*, 2017, **85**, 435–444.

37 Y. Zong, T. W. Bice, H. Ton-That, O. Schneewind and S. V. Narayana, *J. Biol. Chem.*, 2004, **279**, 31383–31389.

38 G. R. Grimsley, J. M. Scholtz and C. N. Pace, *Protein Sci.*, 2009, **18**, 247–251.

39 N. Ancona, A. Bastola and E. Alexov, *J. Comput. Biophys. Chem.*, 2023, **22**, 515–524.

40 R. L. Thurlkill, G. R. Grimsley, J. M. Scholtz and C. N. Pace, *Protein Sci.*, 2006, **15**, 1214–1218.

41 Z. Wu, H. Hong, X. Zhao and X. Wang, *Bioresour. Bioprocess*, 2017, **4**, 13.

42 A. Tantipanaporn and M.-K. Wong, *Molecules*, 2023, **28**, 1083.

43 X. Pan, H. Wang, C. Li, J. Z. H. Zhang and C. Ji, *J. Chem. Inf. Model.*, 2021, **61**, 3159–3165.

44 J. Wu, Y. Kang, P. Pan and T. Hou, *Drug Discovery Today*, 2022, **27**, 103372.

45 C. Ardino, F. Sannio, C. Pasero, L. Botta, E. Dreassi, J. D. Docquier and I. D'Agostino, *Mol. Diversity*, 2023, **27**, 1489–1499.

46 H. Hirakawa, S. Ishikawa and T. Nagamune, *Biotechnol. J.*, 2015, **10**, 1487.

47 L. Chen, J. D. Cohen, X. Song, A. Zhao, Z. Ye, C. J. Feulner, P. J. Doonan, W. S. Somers, L. Lin and P. R. Chen, *Sci. Rep.*, 2016, **6**, 31899.

48 Z. Su, Y. Huang, Q. Zhou, Z. Wu, X. Wu, Q. Zheng, C. Ding and X. Li, *Protein Pept. Lett.*, 2006, **13**, 785–792.

49 Y. Ma, J. Yu, J. Lin, S. Wu, S. Li and J. Wang, *BioMed Res. Int.*, 2016, 3758941.

50 D. W. Barnes, *J. Cell Biol.*, 1982, **93**, 1–4.

51 J. Y. Song, S. W. Lee, J. P. Hong, S. E. Chang, H. Choe and J. Choi, *Cancer Lett.*, 2009, **283**, 135–142.

52 R. C. Johnston, K. Yao, Z. Kaplan, M. Chelliah, K. Leswing, S. Seekins, S. Watts, D. Calkins, J. Chief Elk, S. V. Jerome, M. P. Repasky and J. C. Shelley, *J. Chem. Theory Comput.*, 2023, **19**, 2380–2388.

